Enliven Therapeutics

Enliven is a biotechnology company focusing on the discovery and development of next generation precision oncology therapeutics.

Enliven's mission is to help people with cancer to not only live longer, but live better.

Enliven Therapeutics was founded in July 2019 by Sam Kintz, Joe Lyssikatos, and Anish Patel. The company is headquartered in Boulder, Colorado.

 

Enliven aims to address existing and emerging unmet needs with a precision oncology approach that improves survival and enhances overall patient well-being.

 

Enliven's discovery process combines deep insights from clinically validated biological targets and differentiated chemistry to design potentially first-in-class or best-in-class therapies.

 

Enliven's drug candidates are designed to address issues such as tolerability, combinability, resistance, and disease escape through brain metastases. It's science addresses the challenges of existing therapies–tolerability, combinability and emerging issues like resistance and disease progression–with a novel precision oncology approach.

 

Enliven is backed by Cormorant Asset Management, Surveyor Capital, OrbiMed, Roche Venture Fund, Janus Henderson Investors, 5AM Ventures, Boxer Capital, Logos Capital, and others. The company closed an $85M Series B round on Jan 19, 2022. This brings Enliven's total funding to $140M to date.

 

 

  • Year founded: 2019
  • Funding Info: $140M over 3 Rounds (Latest Funding Type: Series B)
  • Yearly Revenue: NA
  • Employee Size: 11-50
  • Business Valuation: NA
  • City/Town: Boulder
  • State: Colorado
  • Country: United States
Related businesses